InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,310.77
(
2.26%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 178441

Wednesday, 07/30/2014 3:13:31 PM

Wednesday, July 30, 2014 3:13:31 PM

Post# of 251706
INCY, Roche ink non-exclusive clinical collaboration to test IDO1 inhibitor (INCB24360) with PD-L1 inhibitor (MPDL3280A):

http://finance.yahoo.com/news/incyte-announces-clinical-trial-agreement-123000170.html

Incyte will be responsible for conducting the study and the results will be used to determine whether further clinical development of this combination is warranted. Further details of the agreement were not disclosed.

Similar to INCY’s non-exclusive clinical collaborations with AZN (#msg-101978540) and BMY (#msg-102526464).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up